2 recruiting, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Tumor Imaging: new trials by email Literature Review of Tumor Imaging trials Research Report on Tumor Imaging
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma Obinutuzumab, Glofitamab, Pirtobrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | University of California, San Francisco | 30 | 2024-06-11 | 2026-10-01 |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection - Carcinoma, Non-Small-Cell Lung | Recruiting | Merck Sharp & Dohme LLC | 1065 | 2019-12-19 | 2026-10-29 | |
| Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine Safety Laboratories, AE Assessment, Physical Exam - Metastatic Pancreatic Cancer | Phase 2 | Terminated | HonorHealth Research Institute | 1 | 2019-10-17 | 2023-10-18 |
Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Mantle-Cell (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
HonorHealth Research Institute (1) · Merck Sharp & Dohme LLC (1) · University of California, San Francisco (1)
United States (3) · Canada (1) · Hungary (1) · Israel (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1) · Taiwan (1) · Ukraine (1)
Gayle Jameson, ACNP-BC (1) · Madhav Seshadri, MD (1)